Kairos Pharma Ltd. (KAPA)
1.73
-0.08
(-4.42%)
USD |
NYAM |
Sep 18, 16:00
1.75
+0.02
(+1.16%)
After-Hours: 20:00
Kairos Pharma Enterprise Value : 2.669M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 2.669M |
| September 17, 2026 | 2.914M |
| September 16, 2026 | 2.914M |
| September 15, 2026 | 3.036M |
| September 14, 2026 | 3.005M |
| September 11, 2026 | 2.754M |
| September 10, 2026 | 2.516M |
| September 09, 2026 | 2.454M |
| September 08, 2026 | 2.791M |
| September 04, 2026 | 3.005M |
| September 03, 2026 | 2.485M |
| September 02, 2026 | 2.210M |
| September 01, 2026 | 2.424M |
| August 31, 2026 | 2.516M |
| August 28, 2026 | 2.454M |
| August 27, 2026 | 2.537M |
| August 26, 2026 | 2.944M |
| August 25, 2026 | 2.691M |
| August 24, 2026 | 2.344M |
| August 21, 2026 | 3.587M |
| August 20, 2026 | 3.696M |
| August 19, 2026 | 4.007M |
| August 18, 2026 | 4.020M |
| August 17, 2026 | 4.326M |
| August 14, 2026 | 4.679M |
| Date | Value |
|---|---|
| August 13, 2026 | 5.086M |
| August 12, 2026 | 4.971M |
| August 11, 2026 | 5.159M |
| August 10, 2026 | 4.872M |
| August 07, 2026 | 5.644M |
| August 06, 2026 | 5.729M |
| August 05, 2026 | 4.444M |
| August 04, 2026 | 4.341M |
| August 03, 2026 | 4.015M |
| July 31, 2026 | 3.932M |
| July 30, 2026 | 3.799M |
| July 29, 2026 | 3.780M |
| July 28, 2026 | 3.972M |
| July 27, 2026 | 4.011M |
| July 24, 2026 | 3.480M |
| July 23, 2026 | 3.756M |
| July 22, 2026 | 4.073M |
| July 21, 2026 | 5.044M |
| July 20, 2026 | 4.268M |
| July 17, 2026 | 4.015M |
| July 16, 2026 | 4.656M |
| July 15, 2026 | 4.187M |
| July 14, 2026 | 4.658M |
| July 13, 2026 | 4.613M |
| July 10, 2026 | 4.930M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.980B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.388M |
| Total Expenses (Quarterly) | 1.388M |
| EPS Diluted (Quarterly) | -0.4536 |
| Earnings Yield | -112.6% |
| Normalized Earnings Yield | -108.72 |